The effect of preoperative docetaxel, cisplatin and capecitabine on serum RUNX3 [runt-related transcription factor 3] hypermethylation status in patients with gastric and lower oesophagus adenocarcinoma

Trial Profile

The effect of preoperative docetaxel, cisplatin and capecitabine on serum RUNX3 [runt-related transcription factor 3] hypermethylation status in patients with gastric and lower oesophagus adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2015

At a glance

  • Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Mar 2012 Actual patient number 21 added as reported by ClinicalTrials.gov.
    • 26 Mar 2012 Planned end date 1 May 2014 added as reported by ClinicalTrials.gov.
    • 26 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top